Loading...
Please wait, while we are loading the content...
Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
| Content Provider | Europe PMC |
|---|---|
| Author | Seidu, Samuel Kunutsor, Setor K Topsever, Pinar Khunti, Kamlesh |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8754244&blobtype=pdf |
| Page Count | 13 |
| Journal | Endocrinology, Diabetes & Metabolism [Endocrinol Diabetes Metab] |
| Volume Number | 5 |
| DOI | 10.1002/edm2.303 |
| PubMed Central reference number | PMC8754244 |
| Issue Number | 1 |
| PubMed reference number | 34636161 |
| e-ISSN | 23989238 |
| Language | English |
| Publisher | John Wiley and Sons Inc. |
| Publisher Date | 2021-10-12 |
| Publisher Place | Hoboken |
| Access Restriction | Open |
| Rights License | This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2021 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. |
| Subject Keyword | RAAS inhibitor SGLT2 inhibitor Type 2 diabetes |
| Content Type | Text |
| Resource Type | Article |
| Subject | Endocrinology, Diabetes and Metabolism |